Welcome to our dedicated page for Lakewood-Amedex SEC filings (Ticker: LABT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Lakewood-Amedex's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Lakewood-Amedex's regulatory disclosures and financial reporting.
Lakewood-Amedex Biotherapeutics appointed Dr. Joseph Tucker to its Board effective April 24, 2026. He will serve until the 2027 annual meeting. The Board agreement requires attendance at two to four meetings per year and reimbursement of pre-approved travel and living expenses.
Dr. Tucker will receive $6,000 per quarter payable in common stock and was granted 33,784 warrants exercisable at $10.00 per share for ten years. The warrants vest in four equal tranches on October 24, 2026, April 24, 2027, October 24, 2027, and April 24, 2028; unvested warrants are cancelled if the Company terminates the agreement.
Lakewood-Amedex Biotherapeutics Inc. appointed Joseph Tucker, Ph.D., a veteran biotechnology executive and current CEO of Enveric Biosciences, to its Board of Directors effective April 24, 2026. He will serve until the company’s 2027 annual meeting of stockholders, and will also join the Finance, Audit and Risk, Compensation, and Corporate Governance and Nominating Committees.
Under a board agreement, Dr. Tucker will attend at least two and up to four board meetings per year and be available for ad-hoc consultations. He will receive $6,000 per quarter in common stock and has been granted 33,784 warrants to purchase common stock at $10.00 per share, vesting in four equal tranches between October 2026 and April 2028 with a 10‑year term. The company highlights his experience raising over $100 million, leading public biotech companies, and executing IPOs, mergers, and acquisitions.
Lakewood-Amedex Biotherapeutics Inc. filed a prospectus registering the resale of up to 4,689,177 shares of common stock by identified stockholders in connection with a planned direct listing on the Nasdaq Capital Market. The resale is a secondary offering by existing holders; the Company will not receive proceeds from those resale transactions. The company has a binding private placement to sell 937,500 Series C Preferred Shares for aggregate gross proceeds of $7,500,000, convertible into Common Stock under specified pricing terms. The firm engaged RBW Capital Partners as financial advisor; RBW is expected to receive 272,219 advisory shares (1.75% of fully diluted shares) as compensation, which are not registered in this offering. The prospectus discloses recent short-term notes of $125,000 aggregate and summarizes 2025 net loss of $(3,847,637) with cash of $236,400 as of December 31, 2025.